Julia Tarasenko – VJRegenMed

Patient-centric innovations in the supply chain

Simon Ng — Mon, 28 Feb 2022 17:56:21 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, gives an overview of patient-centric approaches in improving the supply chain for advanced therapies, which usually cannot be administered at home. Long term storage of therapies will benefit patients who will need further doses and biobanking enables healthy cells to be retained if they are required for manufacturing new products. A decentralized approach is additionally required, especially for patients receiving chimeric antigen receptor (CAR) T-cell therapy, as they will benefit from long-term care from their own homes. This interview took place at Advanced Therapies Week 2022.

The effects of COVID-19 on the advanced therapy supply chain

Simon Ng — Mon, 28 Feb 2022 17:56:20 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, comments on the impact of COVID-19 on the advanced therapy supply chain. Whilst the pandemic has caused great uncertainty within the sector, developers have had to consequently adapt to the changing circumstances and the supply chain has become more robust as a result. As people are now wary of potential setbacks, they are now more diligent in drawing up backup plans. This interview took place at Advanced Therapies Week 2022.

Differences in supply chains in the CGT industry

Simon Ng — Thu, 17 Feb 2022 12:05:00 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, comments on the complexity of the supply chain in the cell and gene therapy (CGT) sector. Due to the nature of the products themselves, the manufacturing, storage and administration of these therapies require a supply chain more complicated than that of standard pharmaceutical products. She additionally emphasizes the need to create a robust supply chain, and adapt to the needs of patients who may have disease with limited treatment options. This interview took place at Advanced Therapies Week 2022.

The logistics of manufacturing allogeneic therapies on a large scale

Simon Ng — Thu, 17 Feb 2022 12:04:59 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, discusses changes that are needed in the supply chain to adapt to an increasing demand in allogeneic therapies. Pivoting to a one-to-many supply chain is crucial to successfully manufacture allogeneic therapies on a larger scale, as well as focusing on local suppliers and storage, especially in the light of the COVID-19 pandemic. She additionally highlights the need to increase biobanking capabilities as the industry shifts to allogeneic therapies. This interview took place at Advanced Therapies Week 2022.

Novel supply chain changes in the advanced therapies space

Simon Ng — Thu, 17 Feb 2022 12:04:55 +0000

Julia Tarasenko, MSc, Marken, Durham, NC, describes recent trends in supply chains within the in the cell and gene therapy (CGT) industry. As COVID-19 has greatly disrupted the supply chain, just-in-time manufacturing has become more popular due to a dwindling supply of materials, and products can be produced in a matter of a few days from the procurement of the active pharmaceutical ingredient such as viral vectors. In spite of the pandemic, clinical trials are ongoing for advanced therapies, but the industry must consequently adapt to increased demand. This interview took place at Advanced Therapies Week 2022.